Comparison of immunogenicity and safety between two paediatric TBE vaccines

Vaccine

Volumn 28, Issue 29, 2010, Pages 4680-4685

  Pöllabauer, Eva Maria ^a   Pavlova, Borislava G ^a   Löw Baselli, Alexandra ^a   Fritsch, Sandor ^a   Prymula, Roman ^b   Angermayr, Rudolf ^c   Draxler, Wolfgang ^a   Firth, Clair ^a   Bosman, Jael ^a   Valenta, Barbara ^a   Harmacek, Peter ^a   Maritsch, Friedrich ^a   Barrett, P Noel ^a   Ehrlich, Hartmut J ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c General Practice   (Austria)

Author keywords

Encepur Children; FSME IMMUN Junior; Paediatric vaccines; Tick borne encephalitis

Indexed keywords

FSME IMMUN; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS STRAIN;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; SINGLE-BLIND METHOD; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 77953230221     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.047     Document Type: Article

References (27)

1. Westway E.G., Brinton M.A., Gaidamovitch S.Y., Horzinek M.C., Igarashi A., Käriäinen L., et al. Flaviviridae. Intervirology 24 (1985) 183-192
2. Haglund M., and Gunther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine 21 Suppl. 1 (2003) S11-S18
3. Randolph S.E. Evidence that climate change has caused "emergence" of tick-borne diseases in Europe?. Int J Med Microbiol 293 April (Suppl. 37) (2004) 5-15
4. Sumilo D., Bormane A., Asokliene L., Vasilenko V., Golovljova I., Avsic-Zupanc T., et al. Socio-economic factors in the differential upsurge of tick-borne encephalitis in Central and Eastern Europe. Rev Med Virol 18 March-April (2) (2008) 81-95
5. Brauchli Y.B., Gittermann M., Michot M., Kraehenbuehl S., and Gnehm H.E. A fatal tick bite occurring during the course of tick-borne encephalitis vaccination. Pediatr Infect Dis J 27 April (4) (2008) 363-365
6. Schmolck H., Maritz E., Kletzin I., and Korinthenberg R. Neurological, neuropsychological and electroencephalographic findings after European tick-borne encephalitis in children. J Child Neurol 20 (2005) 506-508
7. Cizman M., Rakar R., Zakotnik B., Pokorn M., and Arnez M. Severe forms of tick-borne encephalitis in children, Wien Klin. Wochenschrift III 12 (1999) 484-487
8. Logar M., Arnez M., Kolbl J., Avsic-Zupanc T., and Strle F. Comparison of the epidemiological and clinical features of tick-borne encephalitis in children and adults. Infection 28 March-April (2) (2000) 74-77
9. Kunz C. TBE vaccination and the Austrian experience. Vaccine 21 April (Suppl. 1) (2003) S50-S55
10. Rendi-Wagner P., Kundi M., Zent O., Dvorak G., Jaehnig P., Holzmann H., et al. Persistence of protective immunity following vaccination against tick-borne encephalitis-longer than expected?. Vaccine 22 (2004) 2743-2749
11. Wittermann C., Schöndorf I., and Gniel D. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine 27 March (10) (2009) 1661-1666
12. World Medical Association, 55th General Assembly, Declaration of Helsinki, Tokyo, 2004.
13. Adner N., Leibl H., Enzersberger O., Kirgios M., and Wahlberg T. Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent/detergent treated, FSME-BULIN S/D in healthy volunteers. Scand J Infect Dis 33 (2001) 843-847
14. ® 0.5 mL in adults aged 18-67 years. Hum Vaccin 5 August (8) (2009) [Epub ahead of print]
15. Kießig S.T., Abler U., Risse P., Friedrich J., Heinz F., and Kunz C. Problems of cut-off level determination in enzyme immunoassays: the case of TBE-ELISA. Klin Lab 11 (1993) 877-886
16. Common Toxicity Criteria. Version 2.0; 30 April 1999. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ ctcv20_4-30-992.pdf [accessed on 18 December 2008].
17. Marcy SM, Kohl KS, Dagan R, Nalin D, Blum N, Jones MC, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004;22:551-6.
18. Nam J.-M. Sample size determination in stratified trials to establish the equivalence of two treatments. Stat Med 14 (1995) 2037-2049
19. Swarbrick J., and Boylan J.C. Encyclopedia of pharmaceutical technology vol. 16 (1997), Marcel Dekker, New York
20. Chang M., Shi Y., Nail S.L., HogenEsch H., Adams S.B., White J.L., et al. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 19 April (20-22) (2001) 2884-2889
21. Bröker M., and Schöndorf I. Are tick-borne encephalitis vaccines interchangeable?. Expert Rev Vaccines 5 (2006) 461-466
22. Heinz F.X., Holzmann H., Essl A., and Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25 (2007) 7557-7567
23. Marth E., and Kleinhappl B. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine 20 November (3-4) (2001) 532-537
24. Ehrlich H.J., Pavlova B.G., Fritsch S., Poellabauer E.M., Loew-Baselli A., Obermann-Slupetzky O., et al. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 22 December (2) (2003) 217-223
25. Murphy K., Travers P., and Walport M. Janeway's immunobiology. 7th ed. (2008), Garland Science, Taylor & Francis Group, New York and London
26. Morgan M.M., Clayton C.C., and Heinricher M.M. Dissociation of hyperalgesia from fever following intracerebroventricular administration of interleukin-1beta in the rat. Brain Res 1022 1-2 (2004) 96-100
27. Russell F.A., Fernandes E.S., Courade J.P., Keeble J.E., and Brain S.D. Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling. Pain 142 April (3) (2009) 264-274 [Epub 2009 Feb]